What the clinical data actually show at two years

Patients treated with the ChondroFiller injectable collagen scaffold for focal knee cartilage defects consistently report around a 30-point improvement on the IKDC — a validated knee-function score ranging from 0 to 100 — and that gain holds through follow-up extending well beyond twelve months.

The figure is not the product of a single sponsored trial. Across four published knee cohort studies, the mean improvement converges on approximately 30 IKDC points from a baseline of around 48, bringing patients to a functional score of roughly 80. The Jerosch prospective post-market clinical follow-up (PMCF) study, currently the longest available at three years, recorded a mean improvement of 32.4 points that was sustained — and marginally increased — at the three-year mark. That gain exceeds the established minimal clinically important difference (MCID) of 16.7 points by a wide margin, meaning the improvement is not just statistically detectable but genuinely meaningful to patients in daily life.

The most recent independent data come from Simeonov et al., published in the Journal of IMAB in December 2024. In 17 patients with a mean age of 31, Lysholm scale and IKDC scores improved significantly at 3, 6, and 12 months (p<0.05). Importantly, the difference between the 6-month and 12-month scores was not statistically significant — suggesting that functional recovery largely consolidates within the first year rather than continuing to build through month 24.

For patients trying to gauge what to expect, this matters practically: the evidence suggests most of the subjective benefit is established well before the two-year mark. The complication rate across published cohorts is approximately 0%, with reoperation rates of 3–8% — a safety profile that sits considerably below that of more invasive cartilage procedures.

Why the second year matters even when patients feel better

Feeling better by month six is genuinely good news — but it does not mean the scaffold has finished its work. The collagen matrix continues to integrate and remodel structurally through the second year, and this biological maturation is largely invisible to the patient until it is measured on MRI.

MOCART — an MRI-based scoring system used to assess the quality and integration of cartilage repair tissue — captures this trajectory directly. In European studies, MOCART scores rose from a mean of 65.3 at four weeks to between 81.6 and 84.3 at one year, indicating progressive structural maturation well after subjective symptoms had stabilised. Published data currently peak at twelve months rather than twenty-four, so the two-year structural picture rests on the direction of that trajectory rather than a dedicated two-year endpoint trial — a distinction worth acknowledging honestly.

This is why MRI follow-up retains value even in patients who are symptom-free: it confirms that the scaffold has integrated appropriately and that the repair tissue is hyaline-like rather than fibrous. That quality of repair tissue is itself shaped by the precision of scaffold placement. Because flush application supports healthy hyaline-like formation whilst overfilling is associated with fibrous healing, how accurately the collagen gel is delivered into the defect has a direct bearing on what the follow-up MRI is likely to show — and ultimately on the durability of the result.

Which patients are most likely to benefit

The scaffold is designed for a specific clinical scenario: a focal, contained full-thickness cartilage defect — Grade III or IV — sitting within an otherwise reasonably healthy joint. It is not appropriate for generalised osteoarthritis, where the joint environment itself is compromised.

That distinction matters mechanically. ChondroFiller works through acellular matrix-induced chondrogenesis — the collagen gel provides a physical structure into which progenitor cells from the surrounding synovium and subchondral bone migrate, mature, and begin producing repair tissue. In a joint where that cellular recruitment signal is diminished by widespread degeneration, the scaffold has less to work with. Younger, active patients with isolated defects represent the population in whom published outcomes are most consistently strong; the Simeonov 2024 cohort — deliberately restricted to patients under the defect-size threshold of 2 cm² — reflects that selection logic.

Defect size up to 6 cm² can be treated in a single outpatient session under ultrasound guidance, which compares favourably with microfracture's size ceiling and avoids the two-stage pathway required for ACI or MACI. Patients with larger or multi-focal disease, or those with significant background OA, may be better served by viscosupplementation, a biologic support injection, or surgical assessment — and that determination is made through individual consultant review rather than a fixed protocol.

How ChondroFiller is delivered as an injectable scaffold

The name "Liquid Cartilage™" appears frequently in patient-facing materials and refers specifically to a surgical regeneration procedure offered by the London Cartilage Clinic — delivered via keyhole surgery under general anaesthetic. The underlying implant material in both cases is ChondroFiller, but the delivery routes are meaningfully different, and patients researching their options should confirm with their treating team which pathway applies to them.

At MSK Doctors, ChondroFiller is administered as an outpatient, ultrasound-guided injectable scaffold treatment. The collagen gel is placed directly into the defect under imaging guidance; once inside the joint, it sets in situ to form a structured matrix. The mechanism — acellular matrix-induced chondrogenesis, as described above — does not require a surgical approach to function; accurate image-guided placement into a contained defect is what matters.

ChondroFiller holds CE marking as a Class III medical device, placing it in the highest regulatory tier for implantable products in Europe. More than 19,000 procedures have been performed globally across knee, hip, ankle, and small-joint applications, providing a real-world breadth of experience that extends well beyond the controlled study populations discussed in earlier sections.

How ChondroFiller compares to microfracture and ACI at two years

Placing ChondroFiller's two-year data alongside established surgical alternatives requires care, because no published randomised controlled trial has directly compared it to microfracture or ACI/MACI in matched patient populations — an evidence gap patients deserve to know about.

Microfracture is the most widely performed cartilage procedure globally. Its mechanism produces fibrocartilage rather than hyaline-like tissue, and reoperation rates in published series reach as high as 41%, with outcomes often deteriorating in larger defects beyond the two-year mark.

ACI and MACI (autologous chondrocyte implantation and its matrix-assisted variant) do produce hyaline-like repair tissue, with IKDC gains in published cohorts broadly comparable to ChondroFiller's figures. The difference lies in the pathway: both require two separate surgical episodes — cell harvest, then implantation — and published series report complication rates up to 17% and reoperation rates approaching 37%.

ChondroFiller, delivered as a single ultrasound-guided outpatient appointment, carries a safety and reoperation profile — summarised in the clinical data section above — that sits well below either comparator on those procedural metrics.

ACI and MACI remain appropriate options for patients where a surgical approach is clinically justified; the comparison here is not a dismissal of either pathway. ChondroFiller suits a specific indication: a focal, contained defect amenable to an image-guided injectable route. The single-stage, outpatient advantage is clinically meaningful — but what the evidence cannot yet confirm, for want of a head-to-head RCT, is whether it translates to equivalent or superior long-term cartilage quality when populations are properly matched.

Next steps for patients considering this pathway

For patients who have reached this point in their decision-making, the picture is genuinely encouraging — functional gains that hold beyond twelve months, structural maturation continuing through the second year — while the absence of a head-to-head RCT against microfracture or MACI leaves some longer-term questions open. That uncertainty is worth naming, not to discourage, but because realistic expectations form part of good decision-making.

Practical assessment of suitability — which turns on imaging confirmation of a focal, contained defect in an otherwise healthy joint — is available through MSK Doctors consultants at clinics in Sleaford, Lincolnshire and Grantham, without a GP referral and without NHS-style waiting times. The Regeneration Hub at Sleaford and the MFO Life Sciences Lab at Grantham support the diagnostic workup. Patients based in London can access a related pathway through the London Cartilage Clinic, part of the same clinical group.

To arrange a consultant-led assessment, visit mskdoctors.com.